First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug
Allergan, blindness, CRISPR/Cas9, Editas, gene editing, Leber’s Congenital Amaurosis, ophthalmology
0 Comment
Leber’s Congenital Amaurosis